Jakob Lindberg is CEO for Oncopeptides AB and a Venture Partner in the Investor Growth Capital Europe group. He holds a Med. Lic in Molecular Immunology and a MSc in pre-clinical medicine from the Karolinska Institutet, and a BA in Finance and Administration from the Stockholm University. Mr Lindberg has worked as an analyst for Merrill Lynch and consultant for the McKinsey group. He is the co-founder of Cellectricon AB, where he has also served as the CEO
His research interest is on Molecular Immunology and clinical medicine